Authors: De Jong, D Van Hooren, EG Macklon, NS Mannaerts, BMJL Fauser, BCJM

Citation: D. De Jong et al., Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using aGnRH antagonist (orgalutran/antagon) to prevent a premature LH surge: A case report, J AS REPROD, 18(1), 2001, pp. 30-33

Authors: de Jong, D Macklon, NS Eijkemans, MJC Mannaerts, BMJL Bennink, HJTC Fauser, BCJM

Citation: D. De Jong et al., Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon), FERT STERIL, 75(4), 2001, pp. 688-693

Authors: Voortman, G Mannaerts, BMJL Huisman, JAM

Citation: G. Voortman et al., A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim/Puregon dagger) in healthy female volunteers, FERT STERIL, 73(6), 2000, pp. 1187-1193

Authors: Oberye, JJL Mannaerts, BMJL Kleijn, HJ Timmer, CJ

Citation: Jjl. Oberye et al., Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers, FERT STERIL, 72(6), 1999, pp. 1001-1005

Authors: Oberye, JJL Mannaerts, BMJL Huisman, JAM Timmer, CJ

Citation: Jjl. Oberye et al., Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers, FERT STERIL, 72(6), 1999, pp. 1006-1012